Bristol Myers Squibb Company is hopeful that its oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib could offer a new potential mechanism of action to treat systemic lupus erythematosus (SLE), a challenging condition for drug development. The company announced on 1 June that a Phase II trial testing deucravacitinib in SLE met the primary endpoint and that it will advance the drug into Phase III testing in lupus by the end of the year.
Bristol Confident To Move Deucravacitinib Into Phase III Lupus Trial
A Phase II study testing the TYK2 inhibitor in systemic lupus erythematosus met the primary endpoint. CMO Samit Hirawat talked to Scrip about the data and future development.
More from Clinical Trials
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from R&D
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.